BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Rituximab: trial readouts and FDA decisions
5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Karyopharm Therapeutics Inc, Novartis Pharmaceuticals, LaNova Medicines Limited, Epizyme, Inc., Acerta Pharma BV, Loxo Oncology, Inc., Incyte Corporation, Celgene. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2/P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | active not recruiting | 501 |
| 2026-12-30 est. | P2 | Novartis Pharmaceuticals NVS | NCT06388941 Iptacopan in Patients With ANCA Associated Vasculitis | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | active not recruiting | 84 |
| 2027-01-11 est. | P1/P2 | LaNova Medicines Limited | NCT05615974 A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | Malignant Tumors | recruiting | 139 |
| 2027-02-13 est. | P3 | Epizyme, Inc. | NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in | Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma | active not recruiting | 599 |
| 2027-02-15 est. | P3 | Acerta Pharma BV | NCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Lymphoma, Mantle Cell | active not recruiting | 635 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P3 | Loxo Oncology, Inc. | NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | active not recruiting | 600 |
| 2026-09-01 est. | P3 | Incyte Corporation INCY | NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | Diffuse Large B-cell Lymphoma | active not recruiting | 899 |
| 2026-06-19 | P2 | Celgene | NCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | Lymphoma, Follicular | active not recruiting | 95 |
| 2026-06-03 | P3 | Hoffmann-La Roche | NCT04712097 A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a | Relapsed or Refractory Follicular Lymphoma | active not recruiting | 478 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.